GT199600098A - Formulaciones de quinolona inyectables. - Google Patents

Formulaciones de quinolona inyectables.

Info

Publication number
GT199600098A
GT199600098A GT199600098A GT199600098A GT199600098A GT 199600098 A GT199600098 A GT 199600098A GT 199600098 A GT199600098 A GT 199600098A GT 199600098 A GT199600098 A GT 199600098A GT 199600098 A GT199600098 A GT 199600098A
Authority
GT
Guatemala
Prior art keywords
injectable
complementary
quinolone
formulations
injection
Prior art date
Application number
GT199600098A
Other languages
English (en)
Inventor
Wayne Alan Boettner
Peter Connor Canning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT199600098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT199600098A publication Critical patent/GT199600098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UNA SOLUCION FARMACEUTICA ACUOSA QUE ES ADECUADA PARA INYECCION EN UN HUESPED, QUE COMPRENDE DANOFLOXACINA O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES EN UNA CANTIDAD SUFICIENTE PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS Y, (1) UN COMPUESTO DE MAGNESIO O, (2) UN COMPUESTO DE CINC MEZCLADO CON UN DISOLVENTE COMPLEMENTARIO, ESTANDO PRESENTES DICHOS COMPUESTOS Y DICHOS DISOLVENTES COMPLEMENTARIOS EN CANTIDADES QUE SON SUFICIENTES PARA MEJORAR LA TOLERANCIA EN EL SITIO DE LA INYECCION. LA DANOFLOXACINA ES EL ACIDO 1CICLOPROPIL6FLUORO7{(1S, 4S)5METIL2.5DIAZABICICLO [2.2.1] HEPT2IL} 4OXO3QUINOLIN CARBOXILICO.
GT199600098A 1995-12-21 1996-12-19 Formulaciones de quinolona inyectables. GT199600098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (1)

Publication Number Publication Date
GT199600098A true GT199600098A (es) 1998-06-12

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199600098A GT199600098A (es) 1995-12-21 1996-12-19 Formulaciones de quinolona inyectables.

Country Status (42)

Country Link
US (1) US5811130A (es)
EP (1) EP0868183B1 (es)
JP (1) JP3416145B2 (es)
KR (1) KR100402570B1 (es)
CN (1) CN1104899C (es)
AP (1) AP706A (es)
AR (1) AR005147A1 (es)
AT (1) ATE212551T1 (es)
AU (1) AU709474B2 (es)
BG (1) BG63933B1 (es)
BR (1) BR9612230A (es)
CA (1) CA2239352C (es)
CO (1) CO4480098A1 (es)
CZ (1) CZ293747B6 (es)
DE (1) DE69618987T2 (es)
DK (1) DK0868183T3 (es)
DZ (1) DZ2146A1 (es)
EG (1) EG24071A (es)
ES (1) ES2167609T3 (es)
GT (1) GT199600098A (es)
HR (1) HRP960607B1 (es)
HU (1) HU227918B1 (es)
IL (1) IL124454A (es)
IS (1) IS2010B (es)
MA (1) MA24035A1 (es)
MX (1) MX9805026A (es)
MY (1) MY117109A (es)
NO (1) NO315734B1 (es)
NZ (2) NZ320545A (es)
OA (1) OA10697A (es)
PE (1) PE25798A1 (es)
PL (1) PL186795B1 (es)
PT (1) PT868183E (es)
RS (1) RS49523B (es)
RU (1) RU2141827C1 (es)
SI (1) SI0868183T1 (es)
SK (1) SK284412B6 (es)
TN (1) TNSN96163A1 (es)
TW (1) TW449475B (es)
UA (1) UA56151C2 (es)
WO (1) WO1997023217A1 (es)
ZA (1) ZA9610780B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
WO2001051089A1 (de) * 2000-01-13 2001-07-19 Merck Patent Gmbh Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
AU2003247793A1 (en) * 2002-06-26 2004-01-19 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
EP1764102A4 (en) * 2004-07-02 2010-08-25 Daiichi Seiyaku Co MEDICINAL COMPOSITION CONTAINING QUINOLONE
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
HUE038814T2 (hu) * 2005-05-18 2018-11-28 Horizon Orphan Llc Aeroszolizált fluor-kinolonok és alkalmazásaik
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
LT1991201T (lt) * 2006-02-10 2018-07-25 Pari Pharma Gmbh Puškiami antibiotikai inhaliaciniam gydymui
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
LT2473170T (lt) 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
JP6675396B2 (ja) 2015-06-02 2020-04-01 杏林製薬株式会社 水性液剤
EP3305296A4 (en) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
MX2019009572A (es) * 2017-02-13 2019-10-02 Bayer Animal Health Gmbh Composicion liquida que contiene pradofloxacina.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
DK0507851T3 (da) * 1989-12-29 1997-08-25 Abbott Lab Quinoloncarboxylsyre-matalion-syrekomplekser
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
CN1104899C (zh) 2003-04-09
MX9805026A (es) 1998-09-30
TW449475B (en) 2001-08-11
EG24071A (en) 2008-05-11
BG102542A (en) 1999-06-30
KR19990076617A (ko) 1999-10-15
SK284412B6 (sk) 2005-03-04
SI0868183T1 (en) 2002-04-30
ATE212551T1 (de) 2002-02-15
EP0868183B1 (en) 2002-01-30
YU69096A (sh) 1999-06-15
NO982842D0 (no) 1998-06-19
CO4480098A1 (es) 1997-07-09
NZ320545A (en) 2000-03-27
PL328001A1 (en) 1999-01-04
AP9600898A0 (en) 1997-01-31
UA56151C2 (uk) 2003-05-15
US5811130A (en) 1998-09-22
OA10697A (en) 2001-05-04
BR9612230A (pt) 1999-07-13
CN1205636A (zh) 1999-01-20
IS4755A (is) 1998-05-25
EP0868183A1 (en) 1998-10-07
JPH11501331A (ja) 1999-02-02
IS2010B (is) 2005-05-13
TNSN96163A1 (fr) 2005-03-15
CA2239352A1 (en) 1997-07-03
CZ193098A3 (cs) 1999-05-12
CA2239352C (en) 2002-06-04
AU7328996A (en) 1997-07-17
JP3416145B2 (ja) 2003-06-16
HUP9903726A2 (hu) 2000-04-28
MY117109A (en) 2004-05-31
HUP9903726A3 (en) 2001-01-29
IL124454A0 (en) 1998-12-06
HRP960607A2 (en) 1998-06-30
NO982842L (no) 1998-06-19
ZA9610780B (en) 1998-06-22
DK0868183T3 (da) 2002-03-25
DZ2146A1 (fr) 2002-10-23
IL124454A (en) 2003-10-31
PT868183E (pt) 2002-06-28
RS49523B (sr) 2006-10-27
NZ501160A (en) 2001-10-26
PE25798A1 (es) 1998-05-21
MA24035A1 (fr) 1997-07-01
HU227918B1 (en) 2012-06-28
SK80798A3 (en) 1999-09-10
RU2141827C1 (ru) 1999-11-27
DE69618987T2 (de) 2002-11-21
ES2167609T3 (es) 2002-05-16
WO1997023217A1 (en) 1997-07-03
BG63933B1 (bg) 2003-07-31
DE69618987D1 (de) 2002-03-14
AP706A (en) 1998-12-04
NO315734B1 (no) 2003-10-20
AR005147A1 (es) 1999-04-14
KR100402570B1 (ko) 2003-12-18
HRP960607B1 (en) 2002-06-30
PL186795B1 (pl) 2004-02-27
AU709474B2 (en) 1999-08-26
CZ293747B6 (cs) 2004-07-14

Similar Documents

Publication Publication Date Title
GT199600098A (es) Formulaciones de quinolona inyectables.
DE68907066D1 (de) Verbesserte formulierungen mit kontrollierter abgabe.
AR030707A1 (es) 9-ALFA-CLORO-6-ALFA-FLUOR-17-ALFA-HIDROXI-16-METIL-17-BETA-METOXICARBONIL-ANDROST-1,4-DIENOS, UN PROCESO PARA SU PREPARACIoN , COMPOSICION FARMACEUTICA, Y EL USO DEL MISMO PARA LA FABRICACION DE MEDICAMENTO
NZ330369A (en) aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester
CO4520281A1 (es) Antifungicos de tetrahidrofurano
ES2102132T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
KR910009240A (ko) 약제학적 또는 치료학적 활성제의 수송 시스템
ES2087916T3 (es) Derivado de pirimidina biciclico, metodo para producir el mismo, y preparacion farmaceutica que contiene el mismo como ingrediente activo.
MD1587B2 (en) Retinoid composition and utilization thereof as therapeutic remedy for topical cutaneous application
ATE139439T1 (de) Pharmazeutische formulierung und pharmazeutisches verfahren
ES2165997T3 (es) Uso de una formulacion farmaceutica pediatrica que comprende amoxicilina y clavulanato.
EA199700201A1 (ru) Парентеральные фармацевтические композиции, содержащие алкиламмониевые соли 2-арилпропиновых кислот
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
SE9602442D0 (sv) Administration of pharmaceuticals
ATE246192T1 (de) Ethyliden-derivate tricyclyscher carbapenems
PT96303A (pt) Processo para a preparacao de novos derivados do acido piperidinocarboxilico com accao anestesica local e analgesica e de composicoes farmaceuticas que os contem
PT736029E (pt) Sulfamatos de pseudofructopiranose anticonvulsivos
DE68917937T2 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
ES2139965T3 (es) Benzoilguanidinas sustituidas con grupos de caracter basico, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
DE68906572D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EA199700095A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая индолкарбоновую кислоту
FI893677A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 6-fluori-3,5-dihydroksikarboksyylihappojen ja niiden johdannaisten valmistamiseksi
ES2144844T3 (es) Derivados ureido biologicamente activos utiles en el tratamiento de la esclerosis en placas.
GB1332697A (en) Benzodiazepine derivatives
ES2112517T3 (es) Antibioticos ge 37468 a, b y c.